ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 804,43
1,47%
DAX
18 518,03
-0,44%
Brent Oil
83,465
-1,04%
Bitcoin
64 373,74
-0,74%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
25/08/201715h30GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2017 on 31 August 2017NASDAQ:SMMTSummit Therapeutics Inc
03/08/201713h00GlobeNewswire Inc.Summit Therapeutics to Present at the Canaccord Genuity Growth ConferenceNASDAQ:SMMTSummit Therapeutics Inc
20/07/201713h30Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
22/06/201723h44Dow Jones NewsADRs End Higher; Pharmaceuticals Trade ActivelyNASDAQ:SMMTSummit Therapeutics Inc
22/06/201717h21Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:SMMTSummit Therapeutics Inc
22/06/201713h00GlobeNewswire Inc.Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society CongressNASDAQ:SMMTSummit Therapeutics Inc
15/06/201713h00GlobeNewswire Inc.Summit Therapeutics to Participate in JMP Securities Life Sciences ConferenceNASDAQ:SMMTSummit Therapeutics Inc
14/06/201713h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
13/06/201713h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2017 on 14 June 2017NASDAQ:SMMTSummit Therapeutics Inc
05/06/201713h00GlobeNewswire Inc.Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017NASDAQ:SMMTSummit Therapeutics Inc
23/05/201713h00GlobeNewswire Inc.Summit Announces Key Appointments to Strengthen Research and Development TeamNASDAQ:SMMTSummit Therapeutics Inc
15/05/201713h00GlobeNewswire Inc.Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMDNASDAQ:SMMTSummit Therapeutics Inc
29/04/201700h30GlobeNewswire Inc.Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Stati...NASDAQ:SMMTSummit Therapeutics Inc
30/03/201713h00GlobeNewswire Inc.Summit Therapeutics to Present at the Needham Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
29/03/201713h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Pr...NASDAQ:SMMTSummit Therapeutics Inc
27/03/201713h00GlobeNewswire Inc.Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMDNASDAQ:SMMTSummit Therapeutics Inc
27/03/201713h00GlobeNewswire Inc.Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017NASDAQ:SMMTSummit Therapeutics Inc
15/03/201712h00GlobeNewswire Inc.Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
28/02/201713h00GlobeNewswire Inc.Summit Therapeutics Recognises 10th Annual Rare Disease DayNASDAQ:SMMTSummit Therapeutics Inc
14/02/201721h01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SMMTSummit Therapeutics Inc
02/02/201713h00GlobeNewswire Inc.Summit Therapeutics to Participate in February Investor ConferencesNASDAQ:SMMTSummit Therapeutics Inc
01/02/201713h00GlobeNewswire Inc.Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsNASDAQ:SMMTSummit Therapeutics Inc
18/01/201713h00GlobeNewswire Inc.Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & DevelopmentNASDAQ:SMMTSummit Therapeutics Inc
15/12/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
13/12/201616h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2016 on 15 December 2016NASDAQ:SMMTSummit Therapeutics Inc
16/11/201613h00GlobeNewswire Inc.Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMDNASDAQ:SMMTSummit Therapeutics Inc
06/10/201613h00GlobeNewswire Inc.Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle SocietyNASDAQ:SMMTSummit Therapeutics Inc
04/10/201613h01GlobeNewswire Inc.Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for Europea...NASDAQ:SMMTSummit Therapeutics Inc
04/10/201613h00GlobeNewswire Inc.Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Ut...NASDAQ:SMMTSummit Therapeutics Inc
27/09/201613h00GlobeNewswire Inc.Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular DystrophyNASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

SPI
SP500
S&P 500
EU
DG
Vinci
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
EU
VK
Vallourec
EU
VIV
Vivendi
EU
EN
Bouygues
COIN
ETHUSD
Ethereum
EU
ACA
Credit Agricole
EU
RNO
Renault
EU
ML
Michelin
EU
AF
Air FranceKLM
EU
GLE
Societe Generale
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés